Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03 or MF59
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs PanBlok (Primary) ; AS03A; MF 59
- Indications Influenza A virus infections
- Focus Adverse reactions; Pharmacodynamics
- 14 Feb 2019 Status changed from active, no longer recruiting to completed.
- 23 Feb 2018 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.
- 23 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.